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Since 1986 that Dr Charles E. Murry and his 
colleagues published their discovery about the 
protective effects of ischemic preconditioning (IPC), a 
large number of Pro- and Con- studies have been 
published (1). Besides the protective effects of 
ischemia itself, a number of pharmaceutical agents 
may have protective effects against ischemia known as 
pharmacologic preconditioning. Having a long list of 
agents, these have been under examinations both 
clinically and/or in lab setting. Some disease states 
have been proposed to have a relationship with effects 
of IPC; including diabetes or high altitude diseases (2, 
3). Another variety of IPC is remote IPC which has 
been acting at remote organ tissues (4-6) 
How does IPC with such a wide range of effects 
work? In fact, IPC works both in cardiac and 
neurologic cells; two cell types that are highly 
"ischemia-sensitive"; more interestingly, volatile 
anesthetics-induced preconditioning (part of a larger 
phenomenon known as Anesthetic Preconditioning: 
APC) has protective effects in both cell types; i.e. 
myocardial cells and brain neurons (7). The underlying 
mechanisms for IPC and APC are mainly similar; the 
following items being the most important common 
mechanisms: 
 ATP-sensitive potassium channels in 
mitochondria (mKATP): being one of the most 
important mechanisms in both IPC and APC, leads to 
intracellular protective mechanisms; including but not 
limited to PKCε phosphorylation (a subgroup of 
Protein Kinase C: PKC); among the main 
mitochondrial related mechanisms, inhibition of 
mitochondrial permeability transition pore (mPTP) 
opening, also, " the content of nitric oxide (NO) and 
also, inhibition of nitric oxide synthase (NOS)" and the 
role of mitochondrial connexins could not be neglected 
(7, 8) 
 Reactive Oxygen Species (ROS): when 
mitochondria release small amounts of ROS, both APC 
and IPC could be triggered, leading to their cardio- and 
neuro-protective effects (7, 9, 10) 
 Inflammatory cytokines: a cascade of 
inflammatory cytokines are inhibited due to the 
protective effects of IPC and APC; mainly through 
attenuated activity of NF-κB and the downstream of 
NF-κB-inflammatory cytokines (7, 11-13) 
 Apoptosis: increased anti-apoptotic effects of 
protein Bcl-2, leading to decreased expression of 
caspase-3 are the main mechanisms considered as IPC 
effects through inhibition of apoptosis (7, 14-16) 
Considering the discovered mechanisms of IPC 
and APC, it seems reasonable that both 
cardiomyocytes and brain neurons are benefited from 
volatile anesthetics-induced preconditioning. 
However, the above lines are not the complete 
picture of IPC and further studies, especially regarding 
the clinical aspects of the issue are under way. In this 
issue of the Journal of Cellular and Molecular 
Anesthesia, Anvaripour A, et al. have published their 
study demonstrating that 4% Sevoflurane could not 
have a protective effect on myocardial cells as an 
anesthetic with APC effects (17); a finding in 
controversy with some of the other previous studies. 
These results again confirm the delicate path from 
bench to bedside, which is not always a straight 
forward one. This time, the path goes through 
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